Every claim, every source.

This Trends in Endocrinology and Metabolism review reframes how the body uses ketone bodies — particularly β-hydroxybutyrate (βOHB) — beyond their traditional role as fuel. Newman and Verdin synthesize evidence that βOHB acts as a signaling molecule through at least two mechanisms. First, βOHB binds at least two cell-surface G-protein-coupled receptors (HCAR2/GPR109A and FFAR3/GPR41), modulating lipolysis, sympathetic tone, and metabolic rate. Second, βOHB directly inhibits class I histone deacetylases (HDACs), which means circulating ketones during fasting or ketogenic diets alter gene expression by changing how DNA is packaged. The review traces implications for caloric restriction, longevity, and aging-related diseases. The paper is a key citation for any claim that ketogenic diets and fasting do work beyond "running on fat instead of carbs" — they trigger gene-expression changes via epigenetic mechanisms with downstream effects on stress resistance, inflammation, and metabolic flexibility. The review is highly cited and has shaped how mechanistic ketosis research is framed.

This Cell Metabolism paper combined a large NHANES-based human cohort (2,253 adults followed over 18 years) with mouse experiments to ask whether high protein intake — especially animal protein — drives cancer and mortality risk via IGF-1 and growth-hormone signalling. The headline finding is age-dependent. In adults aged 50–65, those reporting high protein intake (≥20 percent of calories from protein) had a 75 percent higher overall mortality and a fourfold higher cancer death risk over the next 18 years compared to low-protein eaters (under 10 percent of calories). The effect was largely abolished when the protein came from plant sources rather than animal sources. After age 65, the relationship reversed: high protein became protective for cancer and overall mortality — though high protein at any age was associated with a fivefold increase in diabetes mortality. Mouse experiments supported the mechanism: high-protein diets accelerated tumour growth and elevated IGF-1, while protein restriction did the opposite. The interpretation is that protein's relationship with longevity is not monotonic; it depends on age, on the protein source, and on what's being optimized for.

This influential review synthesizes the global picture of forage-fish populations — small pelagic species including sardines, anchovies, herring, menhaden, and capelin — that occupy a central position in marine food webs as the primary trophic link between zooplankton primary production and predator species (larger fish, marine mammals, seabirds). The authors estimate global forage-fish landings at roughly 30 million tonnes per year, with about 90% of that catch directed to non-direct-human-consumption uses, primarily fishmeal and fish oil for aquaculture. The review documents the ecosystem services provided by forage fish, the population dynamics that make them sensitive to over-exploitation, and the co-management requirements (precautionary catch limits, prey-reserve setting) needed to balance fishery yield with ecosystem integrity. The paper is widely cited in conservation policy and is foundational reading for anyone evaluating sardine sustainability in the context of broader marine ecosystem management.

Philip Calder is the leading authority on omega-3 fatty acids and inflammation, and this 2013 BJCP review is his most cited synthesis. The paper traces the multiple mechanisms by which EPA and DHA modulate inflammatory responses: incorporation into cell-membrane phospholipids alters which substrates are available for eicosanoid synthesis (prostaglandins, leukotrienes); direct inhibition of leukocyte chemotaxis, adhesion-molecule expression, and T-cell reactivity; reduced inflammatory cytokine production (TNF, IL-1β, IL-6); disruption of lipid rafts that anchor TLR4 signaling; and generation of pro-resolution lipid mediators (resolvins, protectins) that actively terminate inflammation rather than just dampen it. The paper distinguishes "nutrition-dose" effects (typical 1–2 g/day EPA+DHA from regular fish intake, modest anti-inflammatory shifts) from "pharmacology-dose" effects (3–4 g/day or higher, with measurable effects on rheumatoid arthritis and other clinical inflammatory conditions). The clinical evidence base is strongest for rheumatoid arthritis; weaker and inconsistent for inflammatory bowel disease and asthma.

The 2012 European Union health-claim regulation that defines the regulatory threshold for what counts as a polyphenol-active olive oil. The claim — "olive oil polyphenols contribute to the protection of blood lipids from oxidative stress" — is authorised only for olive oils that deliver at least 5 milligrams of hydroxytyrosol and its derivatives (oleuropein complex and tyrosol) per 20 grams of olive oil consumed. That works out to a tissue-relevant 250 mg per kilogram of olive oil at the daily-intake reference of 20 g. The claim is supported by a body of EFSA-reviewed mechanistic and intervention evidence on phenolic compounds and oxidative stress markers, and is the most widely cited regulatory basis for the "extra virgin olive oil polyphenols are different from refined olive oil" distinction. The regulation is also the EU's reference point for "extra virgin" olive oil quality grading more broadly (acidity ≤0.8%, panel test, polyphenol content). Refined olive oil typically loses 84–87% of polyphenol content during refining.

This consensus review summarizes the human health-effect literature on low-level methylmercury exposure — the form of mercury delivered by dietary fish consumption. The authors evaluate evidence on neurodevelopmental, cardiovascular, neurological, and immunological endpoints across multiple populations and exposure ranges. Their conclusions are nuanced: childhood neurodevelopmental endpoints (subtle decrements in cognitive and motor performance in cohorts with prenatal exposure above background) are the most consistently supported across cohort studies; adult cardiovascular endpoints show much weaker and less consistent evidence; mercury's interaction with the omega-3 benefits of fish consumption complicates the simple dose-response picture for both endpoints. The review distinguishes high-mercury species (tilefish, swordfish, large tuna, shark, king mackerel — to be limited especially in pregnancy) from low-mercury species (small pelagics including sardines, anchovies, salmon — which deliver omega-3 benefits with low mercury exposure). The paper is widely cited in regulatory mercury-exposure guidance.

This study tested 17 different brands of canned sardines, sourced from six countries and bought at retail in eastern Kentucky, for the four most concerning heavy metals in fish: arsenic, cadmium, lead, and mercury. Each brand was analyzed as a composite of 3 to 4 fish using standard atomic-absorption laboratory methods. The headline finding for sardines was clear: mercury was below the 0.09 microgram-per-gram detection limit in every sample tested. That is well under the 1.0 microgram-per-gram FDA action level for predatory fish like tuna and swordfish, and roughly a tenth of the typical canned-tuna averages reported in FDA surveillance data. Arsenic was the highest of the four metals on average (1.06 µg/g), with the highest values appearing in samples from Norway and Thailand; cadmium was highest in Moroccan brands; lead was highest in Canadian brands. The study supports the narrow but important claim that commercial canned sardines, across multiple sourcing countries, are a low-mercury fish.

This meta-analysis pooled 11 randomized controlled trials with 618 total participants to ask whether omega-3 fish oil supplements improve insulin sensitivity in adults. Across all studies and measurement methods, the answer was essentially no. The overall standardized effect size was 0.08 (95% confidence interval -0.11 to 0.28) — statistically indistinguishable from zero. One subgroup analysis was the exception. When researchers used HOMA-IR — a calculation from fasting glucose and insulin — omega-3 supplementation showed a small but statistically significant improvement (effect size 0.30, CI 0.03 to 0.58). On more direct measures of insulin sensitivity, including the euglycemic clamp, the effect was absent. The honest read: at the doses and durations studied, typically 1 to 4 grams of EPA plus DHA per day for weeks to months, omega-3 supplements do not reliably improve insulin sensitivity in adults — though a small HOMA-IR signal exists.

Before this paper, the dominant view was that the brain was metabolically privileged — protected from the autophagy-inducing effects of food restriction so that neurons could maintain function during starvation. Alirezaei and colleagues at the Scripps Research Institute overturned that assumption. Using mice fasted for 24 to 48 hours, they directly measured autophagy markers in cortical neurons and Purkinje cells (the large output neurons of the cerebellum). They found dramatic upregulation: increased numbers of autophagosomes, altered autophagosome characteristics, and decreased neuronal mTOR activity (measured via reduced phosphorylation of S6 ribosomal protein). Transmission electron microscopy directly visualized the autophagosome accumulation. The paper's interpretation: short-term fasting is a simple, non-pharmacological intervention that produces measurable brain autophagy responses. The authors speculated that periodic fasting could be a low-cost approach to engaging neural autophagy as a therapeutic mechanism for protein-aggregation neurodegenerative diseases. The paper has been cited heavily in subsequent fasting-and-brain-health literature and in popular science writing on fasting's neurological benefits.

This 12-week randomized trial compared a carbohydrate-restricted diet (12 percent carb / 59 percent fat / 28 percent protein) with a low-fat diet (56 percent carb / 24 percent fat / 20 percent protein) in 40 adults with atherogenic dyslipidemia — the metabolic-syndrome phenotype defined by high triglycerides, low HDL, central adiposity, and insulin resistance. Both diets were calorie-restricted to similar levels. Both produced improvements, but the carbohydrate-restricted arm consistently outperformed the low-fat arm across nearly every endpoint that defines metabolic syndrome. Glucose dropped 12 percent in the carb-restricted group; insulin fell 50 percent; insulin sensitivity improved 55 percent; body weight dropped 10 percent; adiposity dropped 14 percent. The lipid panel was the most striking divergence: triglycerides fell 51 percent on carb restriction (versus a smaller drop on low-fat), HDL rose 13 percent (versus no change), and the total-cholesterol-to-HDL ratio improved 14 percent more on carb restriction. The paper's interpretation is that the metabolic syndrome is fundamentally a carbohydrate-intolerance phenotype, and that restricting carbs addresses the upstream driver more directly than restricting fat does.

This is the Nature review that brought autophagy to mainstream biomedical attention. Authored by four of the field's most prominent researchers — Mizushima, Beth Levine, Ana Maria Cuervo, and Daniel Klionsky — the paper synthesizes what was known by 2008 about cellular self-digestion as a regulated, disease-relevant process. The authors lay out three core ideas. First, autophagy operates at a basal level in all eukaryotic cells and can be induced by environmental stress — most notably nutrient deprivation, but also hormonal signals, hypoxia, and pathogens. Second, the regulatory pathway centers on mTOR (target of rapamycin), which inhibits autophagy when nutrients are abundant; when mTOR is suppressed (by fasting, by rapamycin, or by genetic loss of function), autophagy is unleashed. Third, autophagy plays both protective and harmful roles depending on context: it prevents neurodegeneration, fights infection, and clears damaged proteins, but cancer cells and some pathogens can hijack the process to survive. The review remains the foundational citation for almost any modern paper on autophagy's role in disease.

This Cell review by Beth Levine and Guido Kroemer — two of the field's most influential autophagy researchers — surveys the role of cellular self-digestion across human disease. The authors organize the field around a core principle: autophagy is fundamentally adaptive, evolved to protect organisms against diverse pathologies including infections, cancer, neurodegeneration, aging, and heart disease. They review how dysregulation of autophagy contributes to specific disease processes — protein-aggregation neurodegenerative disorders (Alzheimer's, Parkinson's, Huntington's), Crohn's disease, cardiomyopathies, and certain cancers. The mTOR pathway sits at the center of the review's mechanistic framework, with TOR-suppressing tumor suppressors (PTEN, TSC1, TSC2) acting as autophagy stimulators and TOR-activating oncogenes (PI3K, Akt) as autophagy inhibitors. The review also acknowledges autophagy's dual-edge nature: prosurvival functions can be deleterious in cancer cells that exploit autophagy to resist treatment. The paper has been cited several thousand times and shaped subsequent autophagy-targeted therapeutics research.

This Aging Cell paper directly addressed a paradox: rodent studies of caloric restriction reliably show IGF-1 reductions and longevity benefits, but the few existing human CR studies had not replicated the IGF-1 effect. Why? Fontana and colleagues compared three groups of human subjects: 28 long-term Calorie Restriction Society members (about 30 percent CR for 5+ years, but maintaining typical Western protein percentages around 24 percent of energy), 28 age-matched moderately protein-restricted vegans (around 10 percent of energy from protein), and 28 sedentary controls. The headline finding overturned the assumption that calories drive the IGF-1 effect: the strict CR group had no significant reduction in IGF-1 versus controls, while the vegans (heavier than the CR group, with more body fat) had significantly lower total and free IGF-1. The paper's conclusion is unambiguous: in humans, low protein intake — not low calorie intake — is what suppresses IGF-1. This finding helped explain why CR-induced longevity benefits in mice have not translated cleanly to humans on standard Western protein intakes, even at low calorie levels.

Refeeding syndrome describes the metabolic and clinical disturbances that occur when severely malnourished or starved patients are fed too aggressively. The mechanism: during prolonged fasting or starvation the body shifts from carbohydrate to fat and protein metabolism, insulin secretion drops, and intracellular minerals — particularly phosphate, potassium, and magnesium — become depleted even when serum levels appear normal. When carbohydrate intake resumes, insulin surges, and glucose, water, and these intracellular minerals shift rapidly back into cells. Serum phosphate, potassium, and magnesium can fall sharply within 24 to 72 hours of refeeding. Thiamine, a cofactor for carbohydrate metabolism, can also become acutely deficient. The combined picture — hypophosphataemia, hypokalaemia, hypomagnesaemia, fluid overload, thiamine deficiency — can precipitate cardiac arrhythmias, congestive heart failure, respiratory failure, seizures, rhabdomyolysis, haemolysis, and sudden death. The review identifies major risk factors: BMI under 16, unintentional weight loss greater than 15 percent in three to six months, little or no nutritional intake for more than ten days, or low pre-feeding levels of phosphate, potassium, or magnesium. Minor risk factors that compound: BMI under 18.5, weight loss greater than 10 percent in three to six months, little or no intake for more than five days, or a history of alcohol misuse, chemotherapy, insulin, antacids, or diuretics. The authors endorse the National Institute for Health and Care Excellence (NICE) approach: in at-risk patients, begin feeding at a maximum of 10 kcal/kg/day (5 kcal/kg/day in extreme cases) and increase slowly over four to seven days; supplement thiamine and a B-vitamin complex before and during the first ten days of feeding; correct and monitor electrolytes daily; restore circulating volume cautiously; and replace phosphate, potassium, and magnesium as needed before and during the early refeeding period. The take-home is straightforward: refeeding syndrome is preventable, but it requires that clinicians recognise risk before reintroducing nutrition and feed slowly with electrolyte and thiamine support, not rush calories into a depleted system.

This is the cleanest human RCT demonstrating that caloric restriction stimulates measurable mitochondrial biogenesis in skeletal muscle. Civitarese and colleagues at Pennington Biomedical Research Center randomized 36 overweight non-obese adults to one of three 6-month interventions: 25 percent calorie restriction (CR), 12.5 percent caloric restriction plus 12.5 percent increase in energy expenditure through exercise (CREX), or weight-maintenance control. Skeletal muscle biopsies were taken at baseline and after 6 months. Both intervention arms showed substantial increases in mitochondrial DNA content — 35 percent in the CR group and 21 percent in the CREX group — with no change in controls. Gene expression of mitochondrial biogenesis regulators rose in both intervention arms: PPARGC1A (PGC-1α), TFAM (mitochondrial transcription factor A), eNOS, SIRT1, and PARL all increased. Notably, the activity of TCA-cycle and beta-oxidation enzymes did not change despite the rise in mitochondrial DNA — suggesting CR produces more mitochondria with similar individual functional capacity, increasing total cellular mitochondrial capacity. DNA damage was reduced in both intervention arms. The paper is the foundational human evidence that caloric restriction does engage the mitochondrial-biogenesis pathway downstream of PGC-1α.

This 2006 PNAS paper from Rafael de Cabo's group at the National Institute on Aging is the foundational rodent mechanistic study for the calorie-restriction → mitochondrial-biogenesis pathway. The researchers fed mice a 40 percent calorie-restricted diet for 6 months and analyzed mitochondrial dynamics in liver and muscle. Three findings are central. First, CR mitochondria consume less oxygen, maintain lower membrane potential, and generate fewer reactive oxygen species than ad-libitum controls — yet they preserve ATP output. The interpretation: CR produces "more efficient" mitochondria that get the same energetic work done with less oxidative collateral damage. Second, the underlying transcriptional driver is PGC-1α (PPARGC1A), which acts via downstream nuclear respiratory factors NRF1 and NRF2 to coordinate mitochondrial biogenesis. Third, eNOS-driven nitric oxide signaling appears to be required: CR-conditioned serum induces mitochondrial biogenesis in cultured myotubes, and the effect is blocked by NO synthesis inhibitors. The paper articulated the molecular framework — PGC-1α, NRFs, eNOS-NO, SIRT1 — that subsequent human studies (Civitarese 2007) confirmed and refined.

This JAMA evidence synthesis remains the most-cited single statement on whether fish consumption is, on balance, beneficial or harmful given the dual presence of cardioprotective omega-3 fatty acids and contaminants like methylmercury and PCBs. Mozaffarian and Rimm reviewed the strength of evidence on both sides for adults and for vulnerable groups (children, women of childbearing age) and reached an unambiguous conclusion: the benefits dominate the risks for adult populations. Their pooled estimate found that modest fish consumption — 1–2 servings per week, particularly fatty species rich in EPA and DHA — reduces coronary death risk by 36 percent and total mortality by 17 percent. They identified an EPA+DHA intake of about 250 mg/day as sufficient for primary cardiovascular prevention. For pregnant women and young children, they recommended species selection to minimize methylmercury exposure (avoiding swordfish, king mackerel, tilefish, shark) while still consuming two servings of lower-mercury fish per week. The paper's framing — benefits substantially outweigh risks — has anchored most subsequent dietary fish guidance.

This is one of the foundational human alternate-day fasting trials, and — importantly — the actual source of the famous "57 percent insulin drop" claim that circulates widely in popular fasting content. Sixteen nonobese adults (8 men, 8 women) fasted every other day for 22 days. The protocol alternated full fasting days with normal eating days. Body weight dropped 2.5 percent and fat mass dropped 4 percent over the three weeks. Resting metabolic rate did not change significantly through day 21, but respiratory quotient fell on day 22 — indicating a clear shift toward fat oxidation, with daily fat oxidation rising by 15 grams or more. Glucose and ghrelin remained essentially stable, but fasting insulin dropped 57±4 percent. Hunger on fasting days remained elevated throughout the protocol, suggesting that adaptation to alternate-day hunger patterns does not happen quickly. The paper concluded that alternate-day fasting is feasible in nonobese adults and produces substantial fat-oxidation and insulin-sensitivity shifts, but adherence is challenging.

This is one of the cleanest human studies on what fasting does to insulin sensitivity. Eight healthy young men (average age 25, BMI around 26) fasted for 20 hours every other day for 15 days. Before and after the protocol, the researchers measured insulin action with the gold-standard test in metabolic research: the euglycemic-hyperinsulinemic clamp, which directly tells you how much glucose insulin can move into tissues at a fixed concentration. After the 15-day intermittent-fasting block, insulin-mediated whole-body glucose uptake rose from 6.3 to 7.3 mg per kilogram per minute — about a 16 percent improvement, statistically significant. Adiponectin, a hormone that improves insulin signaling and tracks metabolic health, rose by more than 50 percent measured against the basal level. The men did not lose meaningful weight, so the change is not explained by fat loss. The study was the first in humans to show that intermittent fasting itself can directly improve how insulin works.

Crossover trial comparing two isocaloric ketogenic diets in healthy adults: one enriched in saturated fat, one enriched in polyunsaturated fat. Both diets supplied roughly 70% of energy as fat with carbohydrate held below 30 grams per day. The authors measured plasma ketones, lipids, and insulin sensitivity across both arms. The headline result for fasting-protocol design: ketogenesis was robust across both fat types — the question is not whether unsaturated fats permit ketosis (they do) but the relative depth of ketosis they produce. The unsaturated-fat arm reached higher β-hydroxybutyrate concentrations than the saturated-fat arm. Insulin sensitivity and lipid markers diverged between arms in ways consistent with the broader saturated-vs-unsaturated literature.